Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00877890 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
254
Enrollment target
20
Study locations

NCT00877890 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by AstraZeneca. The registered enrollment target is 254 participants, below the 2,746-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00877890, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
254 participants
Enrollment target
20
Study locations

Study Summary

This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.

Conditions Studied

Type 2 Diabetes Mellitus

Interventions

  • DRUG exenatide once weekly
  • DRUG exenatide twice daily

Study Locations (20)

California

  • Research Site - Artesia
  • Research Site - Concord
  • Research Site - Encino
  • Research Site - Greenbrae
  • Research Site - La Mesa
  • Research Site - Walnut Creek

Florida

  • Research Site - DeLand
  • Research Site - Hialeah
  • Research Site - Miami
  • Research Site - New Port Richey
  • Research Site - Palm Harbor

Arizona

  • Research Site - Mesa
  • Research Site - Peoria

Indiana

  • Research Site - Avon
  • Research Site - Evansville

Kentucky

  • Research Site - Lexington
  • Research Site - Paducah

Alabama

  • Research Site - Birmingham

Illinois

  • Research Site - Chicago

Michigan

  • Research Site - Detroit

Trial Details

FieldValue
Enrollment Target 254 participants
Start Date 2009-03
Est. Completion 2010-01
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00877890

The ClinicalTrials.gov registry entry for NCT00877890 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,746-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which exenatide once weekly is the first listed.

NCT00877890 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00877890 about?

NCT00877890 is a clinical study titled "A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)". This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolera...

What is the current status of trial NCT00877890?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 254 participants. The study started on 2009-03. Estimated completion is 2010-01.

What conditions does trial NCT00877890 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT00877890?

The interventions under investigation include: exenatide once weekly (DRUG), exenatide twice daily (DRUG).

Who is sponsoring clinical trial NCT00877890?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00877890 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes Mellitus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.